← Atlas Theme · spans 1 topics
Targeting the amylin pathway delivers metabolic weight loss without the severe gastrointestinal penalties of GLP-1 therapies.
By avoiding the biological pathways of the GLP-1 receptor, developers of long-acting amylin analogs can achieve clinically significant weight loss while dramatically reducing rates of nausea and treatment discontinuation.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
GLP-1 Cross-Sector Effects
Zealand Pharma's Petrelintide Phase 2 Data at ADA 2026: Amylin Analog Challenges GLP-1 Dominance with Differentiated Tolerability Petrelintide targets the amylin pathway instead of GLP-1 to achieve significant weight reduction while avoiding the severe gastrointestinal side effects common to incretins.
GLP-1 Cross-Sector Effects
Viking Therapeutics Advances VK2735 Pipeline: Fully Enrolls Subcutaneous Phase 3 and Targets Q4 2026 Oral Phase 3 Initiation Viking's strategic expansion into amylin agonists highlights a broader industry shift toward non-peptide, highly-tolerable mechanisms that do not rely on GLP-1.